Interaction between the Elastin Peptide VGVAPG and Human Elastin Binding Protein by Blanchevoye, Charlotte et al.
HAL Id: hal-02347668
https://hal.archives-ouvertes.fr/hal-02347668
Submitted on 5 Nov 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Interaction between the Elastin Peptide VGVAPG and
Human Elastin Binding Protein
Charlotte Blanchevoye, Nicolas Floquet, Amandine Scandolera, Stéphanie
Baud, Pascal Maurice, Olivier Bocquet, Sébastien Blaise, Christelle Ghoneim,
Benoît Cantarelli, Frédéric Delacoux, et al.
To cite this version:
Charlotte Blanchevoye, Nicolas Floquet, Amandine Scandolera, Stéphanie Baud, Pascal Maurice, et
al.. Interaction between the Elastin Peptide VGVAPG and Human Elastin Binding Protein. Journal
of Biological Chemistry, American Society for Biochemistry and Molecular Biology, 2013, 288 (2),
pp.1317-1328. ￿10.1074/jbc.M112.419929￿. ￿hal-02347668￿
Interaction between the Elastin Peptide VGVAPG and Human
Elastin Binding Protein*□S
Received for publication, September 17, 2012, and in revised form, November 8, 2012 Published, JBC Papers in Press,November 19, 2012, DOI 10.1074/jbc.M112.419929
Charlotte Blanchevoye‡1, Nicolas Floquet‡2, Amandine Scandolera‡1, Stéphanie Baud‡, Pascal Maurice‡,
Olivier Bocquet‡, Sébastien Blaise‡, Christelle Ghoneim‡, Benoît Cantarelli‡, Frédéric Delacoux‡, Manuel Dauchez‡,
Roman G. Efremov§, Laurent Martiny‡, Laurent Duca‡3, and Laurent Debelle‡3,4
From the ‡Laboratoire de Signalisation et Récepteurs Matriciels, FRE CNRS 3184, Université de Reims Champagne Ardenne,
UFR Sciences Exactes et Naturelles, Moulin de la Housse, BP 1039, 51687 Reims Cedex 2, France and the §M.M. Shemyakin and
Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Laboratory of Biomolecular Modeling,
Ul. Miklukho-Maklaya, 16/10, Moscow V-437, 117997 GSP, Russia
Background: The interaction of the peptide VGVAPG with the elastin binding protein is critically involved in aneurysm
progression.
Results: A molecular model of this interaction is proposed and explored using a site-directed mutagenesis strategy.
Conclusion: Three residues, Leu-103, Arg-107, and Glu-137, of elastin binding protein are critical players in this interaction.
Significance:Our data now allow the design of antagonists of VGVAPG.
The elastin binding protein (EBP), a spliced variant of lyso-
somal -galactosidase, is the primary receptor of elastin pep-
tides that have been linked to emphysema, aneurysm and cancer
progression. The sequences recognized by EBP share the
XGXXPG consensus pattern found in numerous matrix pro-
teins, notably in elastin where the VGVAPG motif is repeated.
To delineate the elastin binding site of human EBP, we built a
homology model of this protein and docked VGVAPG on its
surface. Analysis of this model suggested that Gln-97 and
Asp-98 were required for interaction with VGVAPG because
they contribute to the definition of a pocket thought to repre-
sent the elastin binding site of EBP. Additionally, we proposed
that Leu-103, Arg-107, and Glu-137 were essential residues
because they could interact with VGVAPG itself. Site-directed
mutagenesis experiments at these key positions validated our
model. This work therefore provides the first structural data
concerning the interaction of the VGVAPG with its cognate
receptor. The present structural data should now allow the
development of EBP-specific antagonists.
Elastin is the extracellular matrix protein responsible for the
elasticity of vertebrate tissues and is more abundant in tissues
where resilience is required, such as large vessels (1). It is depos-
ited as elastic fibers during early prenatal and postnatal life.
Elastin is constituted of tropoelastin molecules covalently
bound to each other by covalent cross-links (2). Its hydrophobic
and highly cross-linked naturemakes it a very durable polymer,
experiencing essentially no turnover in healthy tissues (3).
The elastin receptor complex (4–6) is derived from the lys-
osomal complex of acid-galactosidase (-gal, EC 3.2.1.23) (4).
It is a heterotrimer comprising a peripheral elastin binding pro-
tein (EBP)5 and twomembrane-associated proteins, neuramin-
idase-1 (EC 3.2.1.18) and the protective protein/cathepsin A
(EC 3.4.16.1).
Although neuraminidase-1 and protective protein/cathepsin
A are identical to the subunits found in the lysosome, EBP is an
enzymatically inactive spliced variant of lysosomal -gal (5, 7,
8). The alternative splicing of -gal primary transcripts leading
to EBP consists of two deletions. The first one deletes exons 3
and 4 and introduces a frameshift; the second one occurs in
exon 6 and restores the initial reading frame. As a consequence,
EBP possesses a unique 32-residue sequence, termed V32,
which is thought to contain its elastin binding site: 83LPG-
SCGQVVGSPSAQDEASPLSEWRASYNSAG114. EBP has no
enzymatic activity but retains the ability to bind galactosugars
(6).When galactosugars bind EBP, the affinity of the elastin site
for its ligand dramatically decreases, leading to their release and
the dissociation of EBP from the complex (5).
The elastin receptor complex is a critical actor of elastogen-
esis (9). In this highly regulated and coordinated phenomenon,
it plays a dual role. First, it protects the newly synthesized tro-
poelastin molecules from prematurely aggregating in the cell
and behaves as a chaperone (10). Second, it accompanies and
delivers the tropoelastin molecules to the cell surface where
elastin assembly occurs (11).
Additionally, this receptor also serves as a functional sensor
for its degradation. Elastin peptides are the result of elastinwear
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and tear due to mechanical fatigue or degradation by elastases
during specific pathophysiological processes (12–14). Elastin
peptide concentration in the blood flow is usually low, but it can
reach high values in aged subjects, notably in those developing
pathologies where elastin is massively degraded such as aneu-
rysms (15, 16). Unlike insoluble fibrous elastin, elastin peptides
promote cell proliferation, cell chemotaxis, angiogenesis, and
proteases release in a wide variety of normal cells (13, 17–19).
The effects promoted by VGVAPG, a sequence repeated six
times in human tropoelastin, are the most documented. As a
consequence, this peptide is regarded as the archetypal elastin
peptide.
It is now established that the catalytic activity of neuramini-
dase-1 is essential for proper functioning of the receptor. It is
required for both elastin assembly (9) and elastin peptide sig-
naling (20). Importantly, this activity requires the presence of
EBP. As a consequence, EBP seems to behave as a molecular
switch allowing neuraminidase-1 activity. Elastin peptides pro-
mote this activity and subsequent signaling, whereas galacto-
sugars block it.
The molecular functioning of the elastin receptor complex
remains unclear. This is notably due to the lack of data concern-
ing the structure of its individual subunits and notably that of
EBP.
In this work, we used homologymodeling to propose the first
molecular model of EBP. According to this model, the EBP-
specific V32 sequence defined a surface pocket stabilized by
interactions between the QDEA and SYNS strings of V32.
Additionally, the docking of VGVAPG on this model suggested
that the Glu-137, Leu-103, and Arg-107 residues of EBP were
critical elements for VGVAPG recognition. These hypotheses
were confirmed by site directedmutagenesis of these individual
residues as COS-7 expressing these mutant forms of EBP had
lost their ability to induce human collagenase-1 (MMP-1) pro-
moter activity following VGVAPG treatment. In conclusion,
our data provide the first detailed structural data on the inter-
action of VGVAPG with EBP and open promising perspectives
in the design of EBP antagonists.
EXPERIMENTAL PROCEDURES
Homology Modeling—A homology model of EBP was built
using MODELLER software (21) and the crystallographic data
available for the unbound Penicillium sp. -galactosidase (Pro-
tein Data Bank code 1TG7) (22). A multiple sequences align-
ment was first generated using ClustalX software (23), which
included all of the -galactosidase sequences available in the
SwissProt database and sharing a maximum E-value of 10 with
the target. The global identity rate between 1TG7 and the target
sequence (EBP formerly termed BGAM_HUMAN, accession
no. P16279) was 30% (55% similar) with an E-value of 3.8 
1015. The main difference between the target and the refer-
ence structure resided in the inserted V32 peptide in the target
model, which was built de novo. The resulting 100 models pro-
duced by the standard protocol of MODELLER were then
ranked according to their objective function values, and the
best one was conserved for the docking experiments.
Docking—Docking of the VGVAPG peptide against the built
EBP structure was performed using the Autodock software
(version 4.0) (24, 25). Lamarckian Genetic Algorithmwas used,
and 250 dockings were performed with a grid resolution of 0.25
Å in the region encompassing the whole V32 peptide. Docking
runs were performed with the default parameters of Autodock
except for population size (200), number of energy evaluations
(106), and the maximum number of generations (500, 000).
Molecular models were graphed with the PyMOL software
available online.
Materials—Reagents for cell culture and transfection reagent
Lipofectamine 2000 were from Invitrogen. The synthetic pep-
tide VGVAPG was purchased from GeneCust (Luxembourg,
Luxembourg). Rabbit polyclonal phospho-specific antibodies
against active forms of ERK1/2 (phosphorylated on Thr-202
and Tyr-204) and anti-ERK1/2 were from Cell Signaling Tech-
nology, Inc. (Beverly,MA, distributed byOzyme, SaintQuentin
en Yvelines, France). Others reagents were from Sigma (Saint-
Quentin Fallavier, France).
Expression Plasmids—The512ColA-luc plasmid encoding
luciferase under the control of the MMP-1 promoter was gen-
erated by cloning the 5 upstream sequence of MMP-1 into the
pGL3Basic reporter plasmid (Promega, Lyon, France), as
described previously (26). The cDNAof human EBP cloned in a
eukaryotic expression vector (pSC/rSV-EBP) was supplied by
Dr. Aleksander Hinek (Hospital for Sick Children, Toronto,
Canada).
Site-directed Mutagenesis—The EBP mutants were obtained
from the wild type plasmid using site-directed mutagenesis
with the QuikChange site-directed mutagenesis kit (Strat-
agene, La Jolla, CA). The sequences of primers used to intro-
duce single pointmutationswithin pSC/rSV-EBP are presented
in Table 1. The reaction was performed in a final volume of 50
l. The sample reaction contained 1 l of Pfu Turbo DNA
polymerase, 5 l of 10 buffer (20 mM MgSO4), 50 ng of pSC/
rSV-EBP preparation, 125 ng of each oligonucleotide, 10 mM
dNTP, and H2O. The reaction was performed using a Master-
cycler gradient thermocycler (Eppendorf, Le Pecq, France) and
subjected to the following program: denaturation of 30 s at
95 °C, 16 cycles of 30 s at 95 °C, 1 min at 55 °C, and 8 min at
68 °C. The sample was digested by 1l of DpnI (10 units/l) for
3 h at 37 °C and chemically transformed into the XL1 Blue
strain. Cells were applied on a LB agar plate containing 50
TABLE 1
Primers used to introduce single point mutations within EBP
The underlined nucleotides correspond to the introduced mutation.
Q97A 5-AGT CCT TCT GCC GCA GAT GAA GCC TCT CC-3
D98A 5-GGG AGT CCT TCT GCC CAA GCT GAA GCC TCT
CCT CTA-3
A100L 5-GTC CTT CTG CCC AAG ATG AAC TCT CTC CTC
TAT CAG AAT GGA GGG-3
L103A 5-GAT GAA GCC TCT CCT GCA TCA GAA TGG AGG
GCC-3
R107A 5-TCT CCT CTA TCA GAA TGG GCG GCC AGT TAT
AAC AGT GC-3
R107K 5-CC TCT CCT CTA TCA GAA TGG AAG GCC AGT
TAT AAC AGT GCA G-3
E137A 5-GGA CCC TTG ATC AAT TCT GCA TTC TAT ACT
GGC TGG CTA G-3
E137D 5-GGA GCA CTG ATC AAT TCT GAC TTC TAT ACT
GGC TGG CTA G-3
E137Q 5-GGA GCA CTG ATC AAT TCT CAA TTC TAT ACT
GGC TGG CTA G-3
Y200A 5-GCA CAG CCC ACC AGC TAC GCC GAC TAT GAT
GCC CC-3
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g/ml ampicillin and incubated overnight at 37 °C. The
obtained clones were sequenced (Institut de Biologie Mole´cu-
laire des Plantes, Strasbourg). The different plasmids were then
concentrated and purified by High Speed Maxi Prep kit (Qia-
gen, Courtaboeuf, France).
Western Blotting—To validate the use of cultured COS-7
cells for further transfection experiments, we first evaluated the
ability of transfected cells to transduce intracellular signals in
the presence of elastin peptides. This was achieved by assessing
the level of ERK1/2 activation after elastin peptide treatment.
Being derived frommammalian cells, COS-7 cells harbor a sim-
ian elastin receptor complex. The ability of these cells to
respond to the presence of elastin peptides was checked when
they were transfected with a plasmid bearing the human wild
type EBP construct.
COS-7 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) containing 4.5 g/liter of glucose, glutamax I,
and pyruvate, supplemented with 10% fetal calf serum and in
the presence of 5% CO2. Cells were then incubated for 24 h in
200 l of serum-free DMEM with a mixture of Lipofectamine
2000 andDNAplasmids for 4 h. Cells were further cultured in a
serum-free medium for 24 h before a 30 min VGVAPG stimu-
lation (200 g/ml) at 37 °C.
106 COS-7 cells were washed twice in ice-cold PBS contain-
ing 50MNa3VO4, scrapped, and sonicated in lysis buffer (PBS,
pH 7.4, 0.5% Triton X-100, 80 mM glycerophosphate, 50 mM
EGTA, 15 mM MgCl2, 1 mM Na3VO4, and protease inhibitor
mixture). Insoluble material was removed by centrifugation
(20,000  g, 20 min, 4 °C). Protein concentrations were deter-
mined by bicinchoninic acid protein assay (Pierce, Rockford, IL;
distributed by Interchim, Montluçon, France). Equal amounts
of proteins were heated for 5 min at 100 °C in Laemmli sample
buffer, resolved by SDS-PAGE under reducing conditions and
transferred to nitrocellulosemembranes. Themembraneswere
placed in blocking buffer (5% (w/v) nonfat dry milk in Tris-
buffered saline/Tween 20 (50 mM Tris, pH 7.5, 150 mM NaCl,
and 0.1% (v/v) Tween 20)) for 1 h at room temperature and
incubated overnight at 4 °C with anti-phospho-ERK1/2
(1:1000) and anti-ERK1/2 (1:500) antibodies. After five wash-
ings with Tris-buffered saline/Tween 20, the membranes were
incubated for 1 h at room temperature in the presence of horse-
radish peroxidase-coupled anti-rabbit antibodies (1:4000 in
blocking buffer). Immunocomplexes were detected by chemi-
luminescence. Blots were quantitated by densitometry using
PhosphorAnalyst software (Bio-Rad).
EBP Mutant Addressing—Human EBP-FLAG mutant con-
structs were obtained by PCR-based approach using the Phu-
sion High-Fidelity DNA polymerase (Finnzymes, Vantaa, Fin-
land). Restriction sites forHindIII andKpnIwere introduced by
PCR immediately adjacent to the initiation and termination
codons of EBP mutants, respectively. After digestion, the
resulting insert was ligated in a p3xFLAG CMV14 vector
encoding a FLAG tag. After sequencing of the constructs,
COS-7 cells were grown in six-well plates and were transiently
transfected by 2 g of EBP-FLAG mutant cDNA. Two wells
were pooled for each mutant. 24 h post transfection, cells were
biotinylated using 500g/ml of biotin. Three washes were then
performedwith cold PBS containingNa3VO4 (50M), and cells
were lysed in cold lysis buffer (50mMNa2HPO4 (pH 8), 300mM
NaCl, 1%TritonX-100 containing 1mMNa3VO4 and a protein-
ase inhibitor mixture). After sonication, the human EBP-FLAG
mutants were solubilized for 1 h at 4 °C. Lysates were centri-
fuged at 20,000  g for 30 min at 4 °C. The protein content of
the resulting surpernatant was assayed, and the biotinylated
proteins were precipitated for 45 min at 4 °C with 20 l of
streptavidin beads. Precipitated proteins were eluted for 5 min
at 100 °C with 100 l Tris/HCL 0.5 M (pH 6.8), 0.5% bromphe-
nol blue, 10% SDS, 20% saccharose, and 25% -mercaptoetha-
nol. Proteins resolved by SDS-PAGE were transferred onto
nitrocellulose membrane (Dutscher, Brumath, France). After
incubation in TBS supplemented with 5% skimmed milk and
1% Tween 20 for 1 h at room temperature, membranes were
incubated overnight at 4 °C with a monoclonal anti-FLAG M2
primary antibody (Sigma) solution (1:1000) in TBS supple-
mented with 5% skimmedmilk and 1% Tween 20. After washes
in TBS supplemented with 1% Tween 20, the biotinylated pro-
teins were revealed using a HRP-conjugated secondary anti-
body (1:3000) and the ECL chemiluminescent reagent (Milli-
pore, Molsheim, France).
Determination of EBP Functionality—COS-7 cells were
grown inDMEMcontaining 4.5 g/liter of glucose, GlutaMAX I,
and pyruvate, supplemented with 10% fetal calf serum and in
the presence of 5% CO2. For transfection experiments, COS-7
cells were grown on 96-well plates to 80% confluence (16,000
cells) in medium containing 10% serum. They were further
incubated for 24 h in 200 l of serum-free DMEM with a mix-
ture of Lipofectamine 2000 andDNAplasmids for 4 h. The ratio
used was 0.2 l of Lipofectamine 2000 for 0.2 g of total plas-
midic DNA divided in 50% of mutant plasmid and 50% of plas-
mid containing a MMP-1 luciferase promoter. After 3 h, cells
were incubated in DMEM for 24 h and stimulated with or with-
out VGVAPG peptide (150 g/ml). When lactose (EBP antag-
onist) was used, cells were preincubated with 1 mM lactose for
3 h before stimulation with VGVAPG. After 16 h, 100 l of
SteadyLite reporter lysis buffer were added (PerkinElmer Life
Sciences), and luciferase activities were measured with a
PerkinElmer TopCount microplate counter.
Statistical Analysis—Experiments were performed in tripli-
cate. Results are expressed as mean  S.E. Comparisons were
made using two-tailed (stimulated versus control) or one-tailed
(stimulated versus own control) Student’s t test. The results
were considered significantly different at p 0.05.
RESULTS
Homology Modeling of EBP—To model EBP, we first gener-
ated a multiple alignment of the sequences of -gal family
members, among which figured Penicillium sp. -galactosid-
ase, which structure had been solved by x-ray crystallography
(22). The sequence of EBP was further aligned, and the corre-
sponding alignment (supplemental Fig. 1) was used to con-
struct EBP models.
The most optimized model, derived from homology model-
ing, is presented in Fig. 1. It encompasses residues 28 to 238 of
EBP (accession no. P16279). Its atomic coordinates are given as
supplemental data. Due to the lack of significant homology
between EBP and Penicillium sp. -galactosidase beyond EBP
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residue 239, our model does not account for the whole struc-
ture of EBP but correctly modeled the supposed region of elas-
tin binding. This is why our model was further refined and
optimized by classical molecular mechanics approaches.
As shown (Fig. 1), the EBP-specific V32 sequence (green) was
located at the surface of the molecule and delimited a horse-
shoe-like pocket. Consequently, we hypothesized that this
pocket could represent the elastin binding site of the molecule,
and we examined it closely.
Previous works (5, 6, 27) had emphasized that the VVGSP-
SAQDEASPL sequence of EBP was important for elastin pep-
tide binding. In particular, the hydrophilic QDEA string (resi-
dues 97–100) was identified as a potential interaction site (28).
We thus hypothesized that these residues could participate to
elastin peptide recognition.
The QDEA motif (Fig. 2A, yellow) was located in the upper
part of the potential elastin binding site and contributed to the
definition of its external limits. Interestingly, the SYNS segment
of V32 (Fig. 2A, residues 109–112,magenta) was very close. In
the model, these sequences defined the right-hand external
limit of the potential elastin binding site. When observed from
another position (Fig. 2B), it appeared that the amide group of
Gln-97 and the hydroxyls of Tyr-110 and Ser-112 were posi-
tioned in a geometry compatible with H-bonding.
Comparison of EBP and -gal Models—The crystal structure
of human -gal has been resolved very recently (29). The com-
parison between our predictive EBPmodel and the experimen-
tal one of -gal is provided in Fig. 3.
The crystal structure of human -gal (Protein Data Bank
code 3THC) is presented in Fig. 3A. Fig. 3B provides the same
view inwhich the sequences spliced in EBP have been removed.
This splicing only impacts the catalytic TIM barrel of the
enzyme (right side of the view). Our EBP model was compared
with the molecular surface of the unspliced enzyme (Fig. 3C)
and further overlaid on the structure of -gal where the spliced
domains had been removed. Strikingly, the agreement between
both models is very good as evidenced in Fig. 3E. Notably, the
sheet structure of the barrel constituting the core of this fold
seems to be barely affected by the splicing. As a consequence
the external helices found in both structures align very well.
This observation greatly supported the validity of our molecu-
lar model of EBP and allowed further docking experiments.
Docking—The VGVAPG peptide is well characterized at the
biological and molecular level (30). This string is repeated six
times in human tropoelastin sequence, and it presents the con-
sensus GXXPG sequence, which is thought to stabilize a type
VIII -turn required for bioactivity of the peptide (30, 31). As a
consequence, we docked this peptide on our molecular model
FIGURE 1.Homologymodel of EBP. This model was built using the MODELLER package as described under “Experimental Procedures.” The surface of EBP is
colored orange. The surface corresponding to V32 is colored green.
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of EBP. The docking procedure yielded severalmodels in which
the VGVAPG sequence was bound onto EBP. Their validities
were assessed by examining their overall potential energy, the
lowest energy meaning the highest affinity.
Most high affinitymodels (in theM range) placedVGVAPG
near or inside of the pocket defined by the V32 sequence. The
best of these models is presented in Fig. 4, A and B, and corre-
sponded to an affinity of 4.85 M for the EBP/VGVAPG inter-
action. This solution placed the VGVAPG peptide inside of the
pocket defined by the V32 sequence of EBP, thus supporting
our former hypothesis that this horseshoe-like depression
could constitute the elastin binding site.
In our docking model, the GVAP string of the bound
VGVAPG adopted a conformation close to a type VIII -turn.
Additionally, the Glu-137, Leu-103, and Arg-107 residues of
EBP (Fig. 3, A and B) seemed to play an important role in the
interaction with VGVAPG. For instance, the hexapeptide
coiled around the hydrophobic Leu-103 residue, whereas Glu-
137 and Arg-107 were orientated to allow ionic interactions
with the charged NH3 and COO extremities of the peptide,
respectively.
The theoretical stability of this EBP/VGVAPG interaction
model was checked by molecular dynamics in explicit solvent
conditions. The results (data not shown) maintained that the
interaction of VGVAPGwith EBP at the supposed elastin bind-
ing site was stable. Indeed, the hexapeptide remained located
inside the binding pocket throughout the three 50-ns simula-
tions performed.
Validation of the Biological System—Following elastin pep-
tide stimulation, the MEK/ERK pathway is activated in COS-7
cells, and this activation could be monitored using a luciferase
assay of MMP-1 promoter activity (20).
As we intended to assay MMP-1 promoter activity in condi-
tions necessitating another transfection (i.e. EBP mutant con-
structs), we first checked the ability of COS-7 to activate their
MEK/ERK signaling cascade when human wild-type EBP was
also expressed. Indeed, in these conditions, the human EBP
competes with the simian EBP from COS-7, and we had to
check that this “hybrid” elastin receptor complex, containing
the transfected EBP associated with endogenous neuramini-
dase-1 and protective protein/cathepsin A, could be correctly
assembled so as to efficiently promote MEK/ERK activation
after interaction with VGVAPG. The data presented in Fig. 5
showed that when COS-7 cells were transfected with an empty
vector and treated with VGVAPG, ERK phosphorylation was
significantly increased as compared with their basal level in the
absence of stimulation (100 to 145%). This indicated that these
cells possessed a functional elastin receptor complex. The
transfection of the WT-EBP construct in these cells in the
absence of stimulation increased slightly ERK activation status
(100 to 116%).We therefore concluded thatWT-EBP transfec-
tion did not substantially modify intrinsic COS-7 ERK activa-
tion when these cells were not stimulated by VGVAPG. How-
ever, increased phosphorylation of ERK was observed in these
transfected cells following VGVAPG treatment (116 to 163%).
This finding strongly suggested that a functional elastin recep-
tor complex could be assembled at the surface of these trans-
fected cells.
As our further experiments required that the luciferase activ-
ity could be compared between transfected cells, we first ana-
lyzed the ability of these cells to express our various EBP con-
structs. COS-7 cells were transfected with the 512ColA-luc
plasmid, and their basal luciferase activity were determined and
compared (Fig. 6A). We observed that the luciferase basal level
was consistent independently of the transfected plasmid. We
thus concluded that the transfection yield was equivalent what-
ever the plasmid considered, suggesting that our further data
could be compared quantitatively.
Finally, we checked the impact of EBP mutations on its
plasma membrane targeting. To this end, FLAG-tagged EBP
mutants were constructed and transfected in COS-7. After
biotinylation of the cell surface, membrane proteins were iso-
lated and the level of EBP-FLAGmutants found at the cell sur-
face was evaluated by Western blot. As shown in Fig. 6B, the
transfection of EBP constructs in COS-7 cells permitted us to
detect EBP-FLAG proteins at their surface. Importantly, the
overall level of EBP protein detected was consistent as no sig-
nificant differences were observed between the mutants as
compared with Y200A. This point suggested that our EBP
FIGURE 2. Analysis of the elastin binding site. A, conformation of the V32
sequence in EBP (green tube). The surface defined by the QDEA (yellow) and
SYNS (magenta) strings are labeled. The arrow indicates the orientation per-
mitting toobserveB.B, stick representationofGln-97 (magenta) and theSYNS
string (yellow) local organization. The thick sticks correspond to residues
(Gln-97 (Q97), Tyr-110 (Y110), Ser-112 (S112)) orienting groups in a local
geometry favorable to H-bonding. The distance between these groups are
reported in angstroms.
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mutants were addressed correctly, allowing us to further ana-
lyze their functionality.
Functionality of EBP Mutants—As we had established that
transfection of human EBP cDNA did not impede the ability of
COS-7 cells to trigger their ERK pathway and that the different
EBP mutants localized well to the plasma membrane, we fur-
ther assessed the functionality of EBP mutants using a lucifer-
ase assay of MMP-1 activity in the presence of VGVAPG. To
this end, COS-7 cells were transfected with both the
512ColA-luc plasmid and amutated EBP construct, and their
ability to develop a luciferase signal following VGVAPG treat-
ment was analyzed.
As shown in Fig. 7, COS-7 cells transfected with amock plas-
mid (empty vector) were responsive to the presence of
VGVAPG, leading to an 80% increase of MMP-1 promoter
activity as compared with their basal rate. This effect could be
blocked by preincubating cells in the presence of lactose indi-
cating the involvement of the elastin receptor complex. This
experiment also showed that doubly transfected COS-7 cells
retained their ability to activate their intrinsic ERK pathway
following VGVAPG treatment (Fig. 5) explaining the onset of
the luciferase signal.
To check that the site-directed mutagenesis process did not
interfere with the cell response, we first co-transfected COS-7
with a human EBP mutant construct bearing the Y200A muta-
tion. This point mutation was chosen because Tyr-200 is an
extremely conserved residue within the -gal family and
because this residue is not located in the V32 sequence (see
supplemental Fig. 1). COS-7 cells expressing this plasmid could
be stimulated with VGVAPG (Fig. 7). The stimulation level
attained was lower than that observed with the empty con-
struct. This lowered stimulation level could be explained by fact
that the assembly of a human EBP with endogenous simian pro-
tective protein/cathepsin A and neuraminidase-1 subunits could
lead to a less efficient signaling by this hybrid complex. Neverthe-
less, we observed that COS-7 transfected with the human EBP
construct could still be significantly stimulated by the addition of
VGVAPG in the medium (45% increase of luciferase signal). This
validated the method used, and we proceeded with other con-
structs. Two types of mutants were constructed.
FIGURE 3. Comparison of the homologymodel of EBP with the crystal structure of human -galactosidase. A, crystal structure of human -gal (Protein
Data Bank code 3THC). The surface of themolecule is colored gray. The secondary structure of the enzyme is represented as a red schematic. The catalytic TIM
barrel is on the right side. B, same representation than A in which the sequences spliced in EBP have been removed. C, molecular model of EBP overlaid on the
surface envelope of human-gal. Themolecule is represented as a cyan schematic. The yellow line corresponds to the backbone trace of V32.D, superposition
of B and C. E, overlay of -gal TIM barrel after splicing (from B) and our EBP model.
Interaction of VGVAPGwith EBP
1322 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 2•JANUARY 11, 2013
 at INSERM
, on January 17, 2013
w
w
w
.jbc.org
D
ow
nloaded from
 
First, we designed mutants bearing a mutation in the QDEA
domain because this region is supposed to be critically involved
in the interaction with elastin peptides (28). These EBP con-
structs bore the followingmutations: Q97A, D98A, and A100L.
When cells were transfected with the corresponding mutant
constructs (Fig. 7, gray bars), the luciferase signal following
VGVAPG treatment was severely attenuated except for the
A100L construct. In this case, the stimulation level was consist-
ent with that observed for the Y200A mutation control con-
struct, but the observed increase was not significant. These
findings suggested that Gln-97 and Asp-98 were important for
VGVAPG binding.
Second, mutants bearing point mutations on residues possi-
bly important for VGVAPG binding were devised on the
ground of the analysis of our VGVAPG docking results. These
EBP constructs bore the following mutations: L103A, R107A,
R107K, E137A, E137D, and E137Q. Strikingly, cells transfected
with constructs bearing one of thesemutants (Fig. 7, black bars)
invariably lost their ability to induce luciferase activity suggest-
ing that these peculiar residues were of utmost importance for
the recognition of VGVAPG by EBP. For instance, the charge-
conservative R107K and E137D mutations did not allowMMP-1
promoter induction, suggesting that the local geometry at these
sites was extremely important for proper VGVAPG binding.
These observations greatly supported our dockingmodel.
DISCUSSION
This work reports the first attempt at describing the struc-
ture and function of the EBP subunit of the elastin receptor
complex. Using structural characteristics of -galactosidases, a
homology model of EBP is proposed. This model (Fig. 1) was
built using a limited portion of EBP sequence (residues 28–238)
that matched the sequence of the TIM barrel active site of Pen-
icillium sp. -galactosidase. As a consequence, the influence of
the rest of the sequence on this peculiar region of the protein
was overlooked.
The examination of human -gal structure reveals that it
possesses three distinct regions (29): a catalytic TIM barrel
domain followed by two -domains. In the crystal structure,
these two regions are structurally independent from the TIM
barrel to which they are connected by a large loop (29). As our
EBP model is derived from the TIM barrel domain sequence,
we feel that the incidence of the rest of the sequence on this
region should be limited.
FIGURE 4.Model of VGVAPGdockedon EBP.A, the VGVAPGpeptide, which
is located in thepocketdefinedby theV32 sequence (green), is representedas
sticks. The three residues stabilizing the interaction are colored in red (Glu-
137), dark blue (Leu-103), and violet (Arg-107). The yellow surface corresponds
to QDEA, the magenta surface corresponds to SYNS. B, other view of the
docked peptide permitting to better appreciate the position of Glu-137, Leu-
103, and Arg-107.
FIGURE 5.VGVAPG activates the ERK pathway in transfected COS-7 cells.
A, Western blots of pERK and ERK levels in COS-7 transfected with an empty
vector or with WT-EBP, after or without VGVAPG treatment. Cells were incu-
bated for 24 h in 200l of serum-free DMEMwith amixture of Lipofectamine
2000 and DNA plasmids for 4 h. Cells were allowed to rest for 24 h in a serum-
free medium before a 30-min VGVAPG stimulation (150 g/ml) at 37 °C. B,
corresponding densitometric analysis. The pERK/ERK ratio is compared with
the corresponding basal situation in the absence of VGVAPG treatment. The
excitability of the system was evaluated using a two-tailed Student’s t test.
Control COS-7 cells versus VGVAPG-treated COS-7 cells (***, p 0.001); EBP-
transfected cells versus VGVAPG-stimulated EBP-transfected cells (###, p 
0.001).
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In our model (Fig. 1), the V32 sequence, which is specific of
EBP, defines a pocket at the surface of the protein. The analysis
of these data has allowed us to propose individual residues that
could be involved in EBP function. A site-directed mutagenesis
analysis of these amino acids was undertaken. Most mutants
failed to trigger intracellular signals, suggesting that these resi-
dues were important for VGVAPG binding and also validated
our model. As a consequence, we propose that the pocket
defined by V32 at the surface of our model is likely the elastin
binding site of EBP.
Our model presents several discrepancies as compared with
the work of Moroy and co-workers (28). In their interaction
model of VGVAPG with the VVGSPSAQDEASPLS peptide,
the QDEA segment of the latter adopts a type I -turn confor-
mation thought to be very important because it exposes Gln so
that it can form threeH-bondswith theVGVAPG skeleton that
coils around it. In our model, the QDEA string adopts a similar
turn structure but, in this conformation, Gln is less exposed to
the solvent. In fact, it interacts with the SYNS string of the V32
sequence. In their initial model, the authors could not see this
interaction as their experiments were performed on a limited
sequence of V32. In our interaction model, the VGVAPG does
not coil around the Gln-97 residue of QDEA but around the
hydrophobic Leu-103 of V32. This possibility could not be seen
FIGURE 6. Effect of EBPmutant transfection on basal luciferase activity and EBPmutant levels at cell surface in transfected COS-7 cells. A, COS-7 cells
were co-transfectedwith constructs encoding luciferase under the control ofMMP-1 promoter, the indicatedmutant EBP constructs, or with an empty vector.
Cellswere then stimulatedwith the VGVAPGpeptide (150g/ml). Basal luciferase activity is expressed as a percentage of the control condition (empty vector).
B, COS-7 cells were transiently transfected by 2g of EBP-FLAGmutant cDNA for 24 h. Cells were further biotinylated with 500g/ml of biotin, washed three
times, and sonicated. Human EBP-FLAGmutantswere then solubilized for 1 h at 4 °C and centrifuged at 20,000 g for 30min at 4 °C. The biotinylated proteins
were precipitated for 45 min at 4 °C with 20 l of streptavidin beads. After elution, retained proteins were analyzed by Western blots using an anti-FLAG
antibody. The presented results correspond to the densitometric analysis of three experiments after normalization. Control, COS-7 cells transfected with the
Y200AEBP-FLAGconstructwithout biotinylation.Gray bars,mutations in theQDEA string;black bars,mutations of Leu-103, Arg-107, andGlu-137.No statistical
difference was observed between the estimated EBP-FLAG levels in transfected cells as compared with the Y200A level (two-tailed Student’s t test). A.U.,
arbitrary units.
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in the model of Moroy and co-workers (28) as the correspond-
ing leucine was at the very C terminus of their peptide and,
consequently, highly exposed to the solvent and thereby flexi-
ble. As a consequence, we suggest that our model would be
more relevant that the former one as it brings additional infor-
mation and presents a good agreement with both experimental
site-directed mutagenesis data and the crystal structure of
human -galactosidase (29).
When residues located in V32 were mutated, a loss of signal-
ing ability was observed in most cases. In the light of the dock-
ing of VGVAPG on EBP (Fig. 4), we suggest that these residues
can contribute to EBP proper functioning in two ways. They
can either participate to VGVAPG interaction (Arg-107 for
example) or contribute to the structural stability of the elastin
binding site. This later situation holds especially for the QDEA
string that could interact with SYNS (Fig. 2B) and contribute to
the overall stability of the site.
Among the tested mutants, the A100L substitution appar-
ently leads to an EBP mutant that still exhibits elastin peptide
affinity. In fact, cells transfected with this construct somehow
retain their ability to be stimulated with VGVAPG (Fig. 7). This
could be explained by the fact that, in our model, the side chain
of this residue is turned toward the center of the protein. As a
consequence, it would not participate in ligand binding, and
mutations at these sites can be tolerated.
The importance of theQDEA string in VGVAPG interaction
has already been suggested (5, 27). Our work supports this view
but also points at the possible importance of the SYNS string of
V32. As suggested by the geometry adopted by these peptides in
our model (Fig. 2B), we propose that they interact together and
thus doing, prevent the elastin binding site from opening up.
That way, the site can accommodate a VGVAPG peptide.
The detailed analysis of the interaction of VGVAPG with
EBPunderlines that three residues are very important: Glu-137,
Leu-103, andArg-107. Indeed, ourmutation experiments show
that these three residues are essential for VGVAPG biological
activity. This proposal is supported by the fact that even con-
servative mutations (E137D, R107K) resulted in a loss of EBP
functionality. Indeed, the loss of a carbon along the acidic side
chain in the E137D mutation shows that the local side chain
positioning is extremely important for VGVAPG recognition.
Likewise, changing the nature of the basic group at position 107
is not tolerated. These two observations strongly suggest that
these residues are essential because they directly contribute to
VGVAPG binding.
Glu-137 is in an ideal position to form an electrostatic bridge
with the N terminus of the peptide. Its side chain points inside
the pocket where it can establish either electrostatic or H-bond
interactions with the backbone of the docked peptide. Similarly,
Arg-107 seems tobeable to cap itsC terminus,whereas thehydro-
phobic Leu-103 forces the peptide to adopt a turn conformation.
Thus doing, the two valyl residues of VGVAPG are orientated so
that they can optimize hydrophobic contacts with Leu-103 for the
first one and V32 VVG sequence for the second.
EBP is known to interactwith various agonists (13, 31–35). In
previous work, we have established that hexapeptides interact-
ing with EBP share the XGXXPG consensus sequence that is
thought to stabilize a type VIII -turn (30, 31). Importantly, the
conformation adopted by VGVAPG in our docking model is
close to a type VIII -turn. In fact, it corresponds to the semi-
open form of the turn described formerly in long term molec-
ular simulations of VGVAPG (30).
Besides the VGVAPG hexapeptide, EBP also binds the tro-
poelastin PGAIPG sequence (31), LGTIPG from laminin-1 (31,
FIGURE 7. Site-directedmutagenesis exploration of VGVAPG binding site. COS-7 cells were co-transfected with constructs encoding luciferase under the
control of MMP-1 promoter, the indicatedmutant EBP constructs, or with an empty vector. Cells were then stimulated with the VGVAPG peptide (150g/ml)
in the absence or presence of 1 mM lactose (EBP antagonist). The results correspond to the luciferase activity measured after VGVAPG treatment. They are
expressed as a percentage of luciferase activity observed for the same situation without treatment. This control value was set to 100% for all experiments
(dashed line).White bars, control experiments; gray bars, mutations in the QDEA string; black bars, mutations of Leu-103, Arg-107, and Glu-137. The reported
significance compares the treated versus untreated cells (one-tailed Student’s t test). **, p 0.01; ***, p 0.001.
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35), and EGFEPG from fibrillin-1 (36). These sequences all
share the XGXXPG consensus and are mostly hydrophobic.
Thus, although the corresponding docking experiments have
not been performed yet, what holds for VGVAPG could also
explain the biological activity of these peptides and they could
adopt the same position than VGVAPG. However, several dif-
ferences could exist notably for the more hydrophilic EGFEPG
fibrillin sequence. Further experiments are required.
Peptides of various lengths are known to bind to EBP, for
example peptides bearing the XGXXPG consensus pattern can
bind efficiently to EBP and can be removed by lactose (37).
Interestingly, theN terminus of this pattern does not have to be
free to allow bioactivity of these longer peptides. Our explana-
tion is that, in this case, the peptide enters deeply in the pocket,
probably guidedbyLeu-103andArg-107 interactions, and folds to
adjust its conformation to the pocket constraints. In this case, the
Glu-137 side chain, which points to the floor of the pocket, could
make strong contributions byH-bonds and/or electrostatic terms
between EBP and the backbone of the agonist.
EBP has also been reported to bind the shorter VGV and
VAPG peptides (32, 38). The fact that these shorter segments
exhibit biological activities related to those VGVAPG possesses
suggest that they share a common binding site. We have noticed
that most of the stabilizing interactions between VGVAPG and
EBP are found on the left part of the pocket, i.e.where the VGVof
VGVAPGoccurs. This observation let us suppose that the tripep-
tideVGVcould dock to this site as the local conformation appears
to properly fit its physicochemical properties. Similarly, the tetra-
peptide VAPG could possibly bind on the left part of the pocket
with stabilizing interactions with Leu-103 and Glu-137. These
hypotheses need further investigations.
Altogether, our results suggest that Glu-137 and Leu-103
could be essential for VGVAPG binding because they mostly
contribute to the stabilization of the complex. Besides, Arg-107
appears to contribute to maintaining the peptide within the
binding site by bridging the C terminus of VGVAPG. This pos-
sibility has been confirmed using molecular dynamics of the
EBP-VGVAPG complex (data not shown).
Finally, EBP is known for its ability to bind lactose, a com-
pound blocking elastin peptide binding. Our data allow us to
propose the following explanation. Of the residues important
for VGVAPG biological activity, Glu-137, which provides the
ionic interaction at theN terminus of VGVAPG, is the only one
that does not belong toV32. This residue is strictly conserved in
the multiple sequence alignment of the -galactosidase family
(Fig. 8A). In fact, according to the alignment and the splicing
FIGURE8.Possible roleofGlu-137intheinterplaybetweentheelastinandgalactolectinsites.A, sequencealignmentshowingthestrictconservationofGlu-137
in-galactosidases.Alignment ruler, *, identity’ :, homology; ., similarity.B, after alignmentof theproteinbackboneof their TIMbarrels (human-Gal andhumanEBP),
the relativepositionsofGlu-268 interactingwithgalactose (in red, fromProteinDataBankcode3THC)andGlu-137 interactingwithVGVAPG(fromourmodel) suggest
apossiblecompetitionbetweengalactoseandVGVAPGforGlu-137binding.ThiscompetitionatacommonsitecouldexplainwhyEBPgalactolectinoccupancyblocks
elastin peptide effects.
Interaction of VGVAPGwith EBP
1326 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 2•JANUARY 11, 2013
 at INSERM
, on January 17, 2013
w
w
w
.jbc.org
D
ow
nloaded from
 
pattern of-gal, that residue corresponds toGlu-268 of-gal, a
residue directly involved in the glycosidase activity of the
enzyme. In fact, Glu-137 is the unique vestige of the catalyti-
cal site of -gal (7) in EBP. It corresponds to the nucleophile
(Glu-268) in this enzyme. Glu-188, the proton donor of
-gal, is absent from EBP as it is removed by the alternative
splicing.
The crystallographic structure of human -galactosidase
bound to galactose is now available (Protein Data Bank code
3THC) (29). In -gal, Glu-188 and Glu-268 are positioned to
interact with galactosugars during the catalysis. Following
splicing, one of these two residues, Glu-138 is removed,
explaining why EBP lacks any enzymatic activity. However, the
residue corresponding to Glu-268 of human -gal (Glu-137 in
EBP) remains. As we proposed that this residue is critical for
binding VGVAPG and because crystallographic data show that
it interacts with galactose, we aligned the TIM barrel backbone
of the human -gal interacting with galactose with that of EBP
docked with VGVAPG. Furthermore, we extracted the atomic
coordinates of Glu-268 and galactose in -gal crystal (Protein
Data Bank code 3THC) and the positions of Glu-137 and
VGVAPG from our model.
The relative position of these compounds, reported in Fig.
8B, strongly suggests that the local presence of a galactose moi-
ety could compete with VGVAPG for Glu-137 binding. This
competition could explain why the elastin and galactolectin
sites of EBP are mutually exclusive. Further numerical simula-
tions and docking experiments of lactose are now underway to
test this hypothesis.
This work presents the first functional model of the subunit
EBP interacting with its VGVAPG ligand. As this interaction is
important in several pathophysiological conditions, this knowl-
edge now permits to envisage the rational design of elastin pep-
tide antagonists that could either block the elastin binding site
of EBP or selectively target Glu-137 as this residue could have a
pivotal role in EBP functions. Thesemolecules could be used to
limit the progression of diseases where elastin degradation
products are abundant and suspected of contributing to the
disease progression.
Finally, our work suggests that Glu-137 of EBP could interact
with both galactosugars and elastin peptides. As such, its involve-
ment could possibly explainwhy galactosugars can remove elastin
peptides from EBP. Further experimental and theoretical experi-
ments are needed to fully understand this point.
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